Research Dosing

Pancragen


Pancragen is a tetrapeptide derived from the pancreas that supports the regeneration and normalization of pancreatic tissue at the cellular level. It contains specific amino acid sequences that correspond to natural regulator peptides found in the pancreas, allowing it to target pancreatic cells, normalize protein synthesis, and improve functional activity of both endocrine (insulin-secreting) and exocrine (digestive enzyme producing) components of the pancreas. Used in research for its ability to regulate pancreatic function and support metabolic homeostasis, particularly in conditions affecting glucose metabolism and pancreatic integrity. Bioregulators, compared to peptides, are comprised of shorter chains of amino acids which, due to their smaller size, have a lower risk of triggering an unwanted immune response. Each bioregulator is tissue-specific and can bind to DNA and regulate gene expression in specific tissues. Whereas larger peptides mainly act through signaling pathways, bioregulators tend to normalize cellular function at the genetic level. Because they can activate or suppress certain genes linked to repair, regeneration, and longevity, their effects are more foundational and long-lasting compared to standard peptides, which usually only act while present during periods of administration.

Benefits

  • Modulates insulin secretion and glucose metabolism
  • Helpful to reduce tolerance to GLP medications
  • The best option to prevent, mitigate, or reverse diabetic complications, including diabetic neuropathy and vascular dysfunction
  • Reduces oxidative stress and inflammation in pancreatic cells
  • Supports pancreatic health and regeneration of islet cells
  • Speeds recovery following pancreatitis or other pancreatic disorders
  • Improves insulin sensitivity
  • Enhances pancreatic response to metabolic stress or injury
  • Normalizes digestive enzyme secretion
  • Improves nutrient assimilation and pancreatic enzyme balance

Possible Side Effects

  • Temporary fatigue or weakness (during metabolic adjustment)
  • Injection site reaction (redness, swelling, and/or itching)
  • Headache
  • Light headedness
  • Mild gastrointestinal upset (nausea, bloating, indigestion)
  • Fluctuations in blood sugar during initial dosing period
  • Rare: Temporary immune activation or modulation symptoms (malaise, fever)

Interactions

  • May increase sensitivity to insulin, Metformin, GLP medications, or SGLT2 inhibitors
  • If used with Thymosin Alpha-1, Vilon, or LL-37, may heighten immune sensitivity temporarily

Contraindications

Absolute

  • Do not use if you are pregnant or breastfeeding
  • Do not use if you have severe acute pancreatitis
  • Do not use if you have active pancreatic cancer

May be able to use under supervision from a medical professional

  • Those with uncontrolled Diabetes Mellitus (especially Type 1)
  • Those with kidney or liver failure
  • Those with pancreatic autoimmune conditions (e.g. autoimmune diabetes/LADA)

PANCRAGEN: 20MG — RECONSTITUTION AND DOSING

20-60 day cycle, 2 or 3 cycles per year

Subcutaneous Administration

Standard Protocol (20-30 days)

Mix with 2mL (200 units) of BAC water

20 units (2mg) every day, for 20-30 days

Extended Protocol (40-60 days)

Mix with 2mL (200 units) of BAC water

20 units (2mg) every other day, for 40-60 days